Post-earnings guidance & market reaction [climaxing]
Key Questions
What was the impact of IPR&D expenses on AbbVie's Q1 earnings?
AbbVie confirmed a $744M Q1 IPR&D drag, resulting in a $0.41 EPS hit. This contributed to cautious expectations ahead of the Q1 earnings report.
What are AbbVie's updated FY26 EPS guidance figures?
AbbVie trimmed its FY26 EPS guidance to $13.96–$14.16, compared to the consensus estimate of $14.52. This adjustment reflects ongoing strategic investments and market dynamics.
What growth projections were provided for Skyrizi and Rinvoq?
Skyrizi and Rinvoq are projected to reach $26B in 2025 (+40% growth) and over $31B in 2026. These immunology drugs are key drivers of AbbVie's future revenue.
What changes were announced to AbbVie's dividend?
AbbVie increased its quarterly dividend by 5.5% to $1.73, yielding 3.2%. This marks a consistent commitment to shareholder returns.
What is the current analyst outlook for AbbVie stock?
RBC maintains an OP $260 rating, advising buy-on-dip with Q1 EPS at $2.59 vs. consensus $2.83. Overall, Moderate Buy consensus with PT $253 (+18% from ~$212.40), citing undervalued P/E of 14x and Q1 catalyst on 4/29.
Confirmed $744M Q1 IPR&D drag ($0.41 EPS hit), FY26 EPS trimmed to $13.96–$14.16 (vs cons $14.52); Skyrizi/Rinvoq $26B '25 (+40%)/$31B+ '26/neuro $10.8B +20%/onc $6.6B/$5B+ M&A beat, div hike 5.5% to $1.73 qtrly/3.2% yield; RBC OP $260 reiterates buy-on-dip/pre-Q1 $2.59 vs $2.83 cons caution; stock ~$212.40 undervalued P/E 14x, Moderate Buy PT $253 (+18%), Q1 4/29 catalyst.